The funding will support the development of remote patient monitoring tools, proprietary sleep diagnostic devices, and comparative clinical studies.
Key takeaways:
- ProSomnus Sleep Technologies secured up to $38 million in funding from Catalio Capital Management to expand its sleep health platform.
- The investment will fund the development of remote patient monitoring and diagnostic devices, as well as clinical studies.
- The capital aims to scale infrastructure to meet growing demand.
ProSomnus Sleep Technologies announced a strategic investment from Catalio Capital Management, LP, committing up to $38 million to accelerate the global expansion of its technology-enabled sleep health platform.
Under the agreement, the funding is designated to advance the development of remote patient monitoring and proprietary sleep diagnostic devices. Additionally, the capital will fund comparative clinical studies and help scale infrastructure.
“Catalio’s investment affirms our mission to address the global public health burden of obstructive sleep apnea with precision, data‑driven medical solutions that create meaningful value loops for patients, clinicians, and payers,” says Len Liptak, CEO of ProSomnus, in a release. “This partnership enables ProSomnus to expand access to care while advancing and scientifically validating our next-generation sensor‑enabled medical devices.”
As part of the transaction, Nicholas von Guionneau, MD, of Catalio has joined the ProSomnus board as an observer.
“Sleep medicine is rapidly shifting toward data-driven, patient-preferred therapies,” says von Guionneau in a release. “ProSomnus is leading that transition with connected oral devices that are clinically effective and consistently used by patients. We’re excited to strategically support the global launch of their next-generation product and broader vision for a scalable connected sleep medicine platform.”
ProSomnus aims to use the investment to ensure growth is defined by patient outcomes rather than just market share.
“This $38 million commitment provides the strategic financial framework to scale our core infrastructure while maintaining a relentless focus on the patient,” says Jason Orchard, chief financial officer of ProSomnus, in a release. “These investments allow us to lower the cost of care, increase treatment efficacy, and create a sustainable model for both our shareholders and the patients we serve.”
